PPARG and Hepatic fibrosis: Rosiglitazone could inhibit NF-κB activation and hepatic fibrosis after bile duct ligation in wild-type mice, but these changes disappeared in PpargΔHEP mice, suggesting a key role for PPARγ in the context of biliary fibrosis [90].